NDAINHALATIONGAS
Approved
Apr 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
HELIUM, USP (helium) by Advanced Solutions Life Sciences. Approved for asthma, obesity, metabolic syndrome and 1 more indications. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HELIUM, USP is an inhaled gas therapy approved in April 2018 for asthma, obesity, metabolic syndrome, and aortic valve stenosis. The product's mechanism of action and pharmacologic class are not specified in available data. It represents a novel inhalation modality for a broad set of cardiovascular and metabolic indications.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30), indicating stable but not rapidly growing commercial opportunity.
Worked on HELIUM, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.